|
PE20040079A1
(es)
*
|
2002-04-03 |
2004-04-19 |
Novartis Ag |
Derivados de indolilmaleimida
|
|
JP2005531609A
(ja)
|
2002-06-05 |
2005-10-20 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
キナーゼ阻害剤としてのシスインドリル−マレイミド誘導体
|
|
EP1513520B1
(en)
*
|
2002-06-05 |
2008-09-24 |
Janssen Pharmaceutica N.V. |
Substituted pyrrolines as kinase inhibitors
|
|
GB0303319D0
(en)
*
|
2003-02-13 |
2003-03-19 |
Novartis Ag |
Organic compounds
|
|
US8598146B2
(en)
|
2003-09-16 |
2013-12-03 |
Garvan Institute Of Medical Research |
Methods for identifying modulators of protein kinase C-epsilon (PKCε) and method of treatment of aberrant glucose metabolism associated therewith
|
|
WO2005039549A1
(en)
*
|
2003-10-27 |
2005-05-06 |
Novartis Ag |
Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation
|
|
EP1687002A4
(en)
*
|
2003-11-10 |
2008-07-23 |
Synta Pharmaceuticals Corp |
CONDENSED HETEROCYCLIC COMPOUNDS
|
|
EP1745037B1
(en)
*
|
2004-01-19 |
2013-01-02 |
Novartis AG |
Indolylmaleimide derivatives as inhibitors for the treatment of graft rejection or autoimmune diseases
|
|
GB0401089D0
(en)
*
|
2004-01-19 |
2004-02-18 |
Novartis Ag |
Organic compounds
|
|
US20070232658A1
(en)
*
|
2004-04-08 |
2007-10-04 |
Jurgen Wagner |
Protein Kinase C Inhibitors for the Treatment of Autoimmune Diseases and of Transplant Rejiction
|
|
GB0410713D0
(en)
*
|
2004-05-13 |
2004-06-16 |
Novartis Ag |
Organic compounds
|
|
AU2005313485B2
(en)
|
2004-12-08 |
2011-02-03 |
Johannes Gutenberg-Universitat Mainz |
3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors
|
|
GB0504203D0
(en)
*
|
2005-03-01 |
2005-04-06 |
Novartis Ag |
Organic compounds
|
|
GB0507918D0
(en)
|
2005-04-19 |
2005-05-25 |
Novartis Ag |
Organic compounds
|
|
EP1885454A2
(en)
|
2005-05-04 |
2008-02-13 |
DeveloGen Aktiengesellschaft |
Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
|
|
GB0511060D0
(en)
|
2005-05-31 |
2005-07-06 |
Novartis Ag |
Organic compounds
|
|
EP2246346B1
(en)
|
2005-07-11 |
2012-10-24 |
Novartis AG |
Indolylmaleimide derivatives as protein kinase inhibitors
|
|
PL2848258T3
(pl)
|
2005-10-26 |
2018-06-29 |
Novartis Ag |
Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta
|
|
NO20220050A1
(no)
|
2005-11-21 |
2008-08-12 |
Novartis Ag |
Neuroendokrin tumorbehandling
|
|
GB0601744D0
(en)
|
2006-01-27 |
2006-03-08 |
Novartis Ag |
Organic compounds
|
|
GB0605691D0
(en)
*
|
2006-03-21 |
2006-05-03 |
Novartis Ag |
Organic Compounds
|
|
GB0613162D0
(en)
*
|
2006-06-30 |
2006-08-09 |
Novartis Ag |
Organic compounds
|
|
JP2010501586A
(ja)
*
|
2006-08-23 |
2010-01-21 |
ノバルティス アクチエンゲゼルシャフト |
眼疾患におけるｐｋｃ阻害剤、特にインドリルマレイミド誘導体の使用
|
|
WO2008051440A1
(en)
*
|
2006-10-20 |
2008-05-02 |
Novartis Ag |
Crystal modifications -3- (1h-ind0l-3-yl) -4- [2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -pyrrole-2, 5-d ione
|
|
CA2671040A1
(en)
*
|
2006-12-07 |
2008-06-19 |
Novartis Ag |
Use of pkc inhibitors in transplantation
|
|
KR20090100363A
(ko)
|
2006-12-19 |
2009-09-23 |
노파르티스 아게 |
키나제 억제제로서의 인돌릴말레이미드 유도체
|
|
CA2679484A1
(en)
*
|
2007-03-09 |
2008-09-18 |
Novartis Ag |
Salts of 3-(1h-ind0l-3-yl)-4-[2-(4-methyl-piperazin-i-yl)-quinazolin-4-yl]-pyrrole-2,5-dione
|
|
KR101591533B1
(ko)
|
2007-05-29 |
2016-02-03 |
노파르티스 아게 |
항-ｉｌ-1-베타 치료법에 대한 신규 적응증
|
|
MX2010003259A
(es)
*
|
2007-09-27 |
2010-04-12 |
Novartis Ag |
Ensayo de monitoreo de farmacos.
|
|
EP2209916B1
(en)
|
2007-11-08 |
2011-12-21 |
Novartis AG |
Gene expression signatures for chronic/sclerosing allograft nephropathy
|
|
AU2008333215B2
(en)
|
2007-12-05 |
2013-06-13 |
Johannes Gutenberg-Universitat Mainz |
Use of 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management
|
|
US8268834B2
(en)
|
2008-03-19 |
2012-09-18 |
Novartis Ag |
Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
|
|
US9752191B2
(en)
|
2009-07-09 |
2017-09-05 |
The Scripps Research Institute |
Gene expression profiles associated with chronic allograft nephropathy
|
|
RU2441000C2
(ru)
*
|
2009-11-27 |
2012-01-27 |
Общество с ограниченной ответственностью "Молекулярные Технологии" |
4-(1-(4-(4-метоксифенилтио)-2,5-диоксо-2,5-дигидро-1н-пирро-3-ил)-1н-индол-3-ил)бутилкарбамимидотиоат и способ его применения
|
|
EP2338486A1
(en)
|
2009-12-18 |
2011-06-29 |
Johannes Gutenberg-Universität Mainz |
3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma
|
|
EP2343291A1
(en)
|
2009-12-18 |
2011-07-13 |
Johannes Gutenberg-Universität Mainz |
3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
|
|
US8791100B2
(en)
|
2010-02-02 |
2014-07-29 |
Novartis Ag |
Aryl benzylamine compounds
|
|
BR112012024585A2
(pt)
*
|
2010-03-30 |
2016-05-31 |
Novartis Ag |
inibidores de pkc para o tratamento de linfomade células b tendo sinalização do receptor de células b ativas crônicas
|
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
|
EP2474541A1
(en)
|
2010-12-23 |
2012-07-11 |
Johannes- Gutenberg-Universität Mainz |
Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
|
|
CN102153605B
(zh)
*
|
2011-03-02 |
2014-02-19 |
福建省微生物研究所 |
一种咪唑立宾的提纯方法
|
|
UY34072A
(es)
|
2011-05-17 |
2013-01-03 |
Novartis Ag |
Derivados sustituidos de indol
|
|
AU2012277391A1
(en)
|
2011-06-27 |
2013-12-19 |
Novartis Ag |
Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
|
|
GB201111427D0
(en)
*
|
2011-07-05 |
2011-08-17 |
Amakem Nv |
Novel bisindolylmaleimides, pan-pkc inhibitors
|
|
WO2013008095A1
(en)
|
2011-07-08 |
2013-01-17 |
Novartis Ag |
Novel pyrrolo pyrimidine derivatives
|
|
US8846712B2
(en)
|
2011-09-12 |
2014-09-30 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
WO2013057711A1
(en)
|
2011-10-21 |
2013-04-25 |
Novartis Ag |
Quinazoline derivatives as pi3k modulators
|
|
AP2014007680A0
(en)
|
2011-12-02 |
2014-06-30 |
Novartis Ag |
Anti-1L-beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
|
|
CA2857302C
(en)
|
2011-12-15 |
2020-08-25 |
Novartis Ag |
Use of inhibitors of the activity or function of pi3k
|
|
US20150148377A1
(en)
|
2011-12-22 |
2015-05-28 |
Novartis Ag |
Quinoline Derivatives
|
|
IN2014CN04174A
(enExample)
|
2011-12-22 |
2015-09-04 |
Novartis Ag |
|
|
EP2847191B1
(en)
|
2012-05-09 |
2016-06-15 |
Sanofi |
Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
|
|
AU2013343059A1
(en)
|
2012-11-07 |
2015-04-09 |
Novartis Ag |
Substituted indole derivatives
|
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫－吡啶并－□衍生物之固體形式
|
|
PL2925366T3
(pl)
*
|
2012-11-29 |
2018-08-31 |
Novartis Ag |
Kombinacje farmaceutyczne
|
|
US9993463B2
(en)
|
2012-12-10 |
2018-06-12 |
Centogene Ag |
Use of maleimide derivatives for preventing and treating cancer
|
|
WO2014090398A1
(en)
*
|
2012-12-10 |
2014-06-19 |
Centogene Ag |
Use of maleimide derivatives for preventing and treating leukemia
|
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
|
WO2014174478A1
(en)
|
2013-04-26 |
2014-10-30 |
Novartis Ag |
Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
|
|
WO2015179773A1
(en)
|
2014-05-22 |
2015-11-26 |
The Scripps Research Institute |
Tissue molecular signatures of kidney transplant rejections
|
|
KR20160060100A
(ko)
|
2013-09-22 |
2016-05-27 |
칼리토르 사이언시즈, 엘엘씨 |
치환된 아미노피리미딘 화합물 및 이용 방법
|
|
US9512084B2
(en)
|
2013-11-29 |
2016-12-06 |
Novartis Ag |
Amino pyrimidine derivatives
|
|
WO2015148868A1
(en)
|
2014-03-28 |
2015-10-01 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
|
BR112016024533A8
(pt)
|
2014-04-24 |
2021-03-30 |
Novartis Ag |
derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas
|
|
KR20160141856A
(ko)
|
2014-04-24 |
2016-12-09 |
노파르티스 아게 |
포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체
|
|
CN106458980A
(zh)
|
2014-04-24 |
2017-02-22 |
诺华股份有限公司 |
作为磷脂酰肌醇3‑激酶抑制剂的氨基吡啶衍生物
|
|
US11104951B2
(en)
|
2014-05-22 |
2021-08-31 |
The Scripps Research Institute |
Molecular signatures for distinguishing liver transplant rejections or injuries
|
|
US10443100B2
(en)
|
2014-05-22 |
2019-10-15 |
The Scripps Research Institute |
Gene expression profiles associated with sub-clinical kidney transplant rejection
|
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
|
MX2018001903A
(es)
|
2015-08-14 |
2018-06-20 |
Novartis Ag |
Inhibidores de mdm2 para el tratamiento de melanoma uveal.
|
|
US9938257B2
(en)
|
2015-09-11 |
2018-04-10 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
|
EP3187495A1
(en)
|
2015-12-30 |
2017-07-05 |
Johannes Gutenberg-Universität Mainz |
3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
|
|
RU2753863C2
(ru)
*
|
2016-02-03 |
2021-08-24 |
Галдерма Ресерч Энд Девелопмент |
Новые биароматические соединения пропинила, фармацевтические и косметические композиции, их содержащие, и их применение
|
|
WO2018175302A1
(en)
|
2017-03-20 |
2018-09-27 |
Sienna Biopharmaceuticals, Inc. |
Polymer conjugates targeting c-src with reduced exposure
|
|
WO2018175340A1
(en)
|
2017-03-20 |
2018-09-27 |
Sienna Biopharmaceuticals, Inc. |
Reduced exposure conjugates modulating therapeutic targets
|
|
US10683297B2
(en)
|
2017-11-19 |
2020-06-16 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
|
CA3083040A1
(en)
|
2018-01-20 |
2019-07-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
|
CN110551103B
(zh)
*
|
2018-05-30 |
2022-08-23 |
北京大学深圳研究生院 |
一种jak3选择性抑制剂
|
|
IL288024B2
(en)
|
2019-05-14 |
2025-12-01 |
Provention Bio Inc |
Methods and compositions for preventing type
|
|
CN121471151A
(zh)
|
2019-05-23 |
2026-02-06 |
诺华股份有限公司 |
Btk抑制剂的晶型
|
|
US12006366B2
(en)
|
2020-06-11 |
2024-06-11 |
Provention Bio, Inc. |
Methods and compositions for preventing type 1 diabetes
|
|
MX2023013851A
(es)
|
2021-05-24 |
2023-12-08 |
Provention Bio Inc |
Metodos para el tratamiento de diabetes tipo 1.
|
|
CN120817930A
(zh)
*
|
2025-06-30 |
2025-10-21 |
湖南科技职业学院 |
吲哚马来酰亚胺衍生物及其应用
|